Pralatrexate

普拉曲沙

Report date: 2023/05/05 17:09:19
NME

Base Information

Drug NamePralatrexate
Drug Alias NamepralatrexatumpralatrexatoFolotynDifoltaPDX
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydrofolate reductase inhibitors
TargetsDihydrofolate reductase
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsLymphoma, T-Cell, Peripheral
Approved Indications in ChinaLymphoma, T-Cell, Peripheral
Original Approved Country/TerritoryUnited States
Original Approved Date2009/09/24
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSpectrum Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnderson Packaging IncAcrotech Biopharma IncAllos Therapeutics Inc +[7] 
Inactive CompaniesNational Cancer InstituteSpectrum Pharmaceuticals IncAllos Therapeutics Ltd
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, T-Cell, Peripheral +[4] 
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[9] 

Other Information

ATC CodeL01BA05
Related LinksWikipediaDrugBankKEGG